Merck

Bicara Therapeutics Expands Clinical Team with Appointments of Jeltje Schulten, M.D., MBA, as SVP of Clinical and Medical Affairs and Rita Dalal, MBBS, MPH, as VP of Clinical Development

Retrieved on: 
Tuesday, March 26, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Carcinoma, Alkermes, Erasmus University Rotterdam, Cetuximab, Patient, SVP, ImClone Systems, Biostatistics, Merck, Epidemiology, Management, University, MBA, Merck Group, Limited partnership, MPH, Therapy, International school, PPD, Eli Lilly and Company, Marketing, Avelumab, Daiichi Sankyo

“We are very pleased to welcome Jeltje and Rita to our talented team.

Key Points: 
  • “We are very pleased to welcome Jeltje and Rita to our talented team.
  • Dr. Schulten received her medical degree from Erasmus University, Rotterdam, Netherlands and her MBA from the International School of Management RSM, Rotterdam, Netherlands.
  • Dr. Rita Dalal is a trained physician with extensive and diverse clinical research experience including in solid tumor oncology.
  • Previously, Dr. Dalal held clinical research scientist positions with Merck Sharp & Dohme Corp. and Eli Lilly and Company.

TaskUs and V7 Announce Strategic Partnership To Enable Enterprise AI Product Delivery

Retrieved on: 
Monday, March 25, 2024
Software, Technology, Artificial Intelligence, Data Management, Concept, Organization, Pressure, Health, Partnership, Fintech, SVP, Roche, GDPR, Social media, Merck, Miele, Bayer, Lawyer, Automated machine learning, Sony, DICOM, Production, Sales

TaskUs and V7 are combining their expertise in AI and data annotation to optimize training data creation for AI product development at some of the world’s biggest technology companies.

Key Points: 
  • TaskUs and V7 are combining their expertise in AI and data annotation to optimize training data creation for AI product development at some of the world’s biggest technology companies.
  • With a proven track record in supporting enterprise retail, healthcare, and asset management industries, the collaboration between V7 and TaskUs offers customers accelerated training data delivery, reduced production costs, and turnkey enterprise solutions.
  • The partnership aims to slash development cycles and enable enterprises to launch AI products significantly faster.
  • "We are thrilled about our strategic partnership with V7, marking a transformative phase in AI product development,” said Phil Tomlinson, SVP, of Global Offerings at TaskUs.

Mirador Therapeutics Launches to Accelerate the Next Generation of Precision Medicines for Immune-mediated Diseases

Retrieved on: 
Thursday, March 21, 2024
Health, Infectious Diseases, Genetics, Other Health, General Health, Pharmaceutical, Biotechnology, Farallon Capital, ARCH Venture Partners, Patient, Merck, Medicine, Investment, Therapy, OrbiMed, Machine learning, Probability, RTW, Pharmaceutical industry

Mirador has raised more than $400 million in financing led by ARCH Venture Partners, with early investments from OrbiMed and Fairmount.

Key Points: 
  • Mirador has raised more than $400 million in financing led by ARCH Venture Partners, with early investments from OrbiMed and Fairmount.
  • “At Mirador, we envision a bold new era of precision medicine for immune-mediated inflammatory and fibrotic diseases driven by speed and superior development accuracy,” said Mark C. McKenna, chairman and CEO of Mirador.
  • To accelerate development, Mirador utilizes Mirador360, its proprietary precision development engine that leverages recent breakthroughs in human genetics and cutting-edge data science.
  • Mirador360 also allows Mirador to develop diagnostics and stratify heterogeneous patient populations for precise clinical development.

MilliporeSigma Invests More than € 300 Million in New Life Science Production Site in Korea

Retrieved on: 
Wednesday, March 20, 2024
Research, Commercial Building & Real Estate, Construction & Property, Genetics, Clinical Trials, Biotechnology, Pharmaceutical, Health, Science, Other Science, Public, Health care, Merck, Messenger, Merck Group, Multimedia, Vaccine, Sigma-Aldrich, Pharmaceutical industry

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, invests more than €300 million into a new Bioprocessing Production Center in Daejeon, South Korea.

Key Points: 
  • MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, invests more than €300 million into a new Bioprocessing Production Center in Daejeon, South Korea.
  • The new site is the largest investment by the company’s Life Science business sector in Asia-Pacific to date and demonstrates its commitment to expanding its capacities in the fast-growing region.
  • The investment is expected to create approximately 300 additional jobs by the end of 2028.
  • Established in 1989, the Life Science business of Merck KGaA, Darmstadt, Germany in Korea has been consistently driving dynamic growth of the science and technology industries with more than 1,700 employees across Life Science, Healthcare and Electronics.

AffyImmune Therapeutics Appoints Matt Britz as Chief Executive Officer and Pete Gelinas as SVP of CMC

Retrieved on: 
Tuesday, March 19, 2024
Research, Genetics, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, CALD, Control, Thyroid cancer, Growth, Bluebird bio, MAA, Drug discovery, Business, MIT, Britz, Patient, SVP, Marketing Authorisation Application, Merck, MSAT, Business development, Acquisition, CMC, Betibeglogene autotemcel, Technology transfer, Senior, MBA, CMCF, Therapy, Takeda, Equinox Group, Dana–Farber Cancer Institute, Multimedia, Chemical engineering, DFCI, Partnership, Biology, BLA, Pharmaceutical industry

AffyImmune Therapeutics, Inc ., a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, affinity-tuned CAR T cell therapies, announced today the appointment of Matt Britz to Chief Executive Officer and Pete Gelinas as Senior Vice President of Chemistry, Manufacturing, and Controls.

Key Points: 
  • AffyImmune Therapeutics, Inc ., a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, affinity-tuned CAR T cell therapies, announced today the appointment of Matt Britz to Chief Executive Officer and Pete Gelinas as Senior Vice President of Chemistry, Manufacturing, and Controls.
  • Matt is well-suited to lead AffyImmune as CEO as the Company accelerates clinical development of AIC100 in thyroid cancer, and in other indications with high unmet medical need.
  • Matt Britz joined AffyImmune in June 2021 as Senior Vice President (SVP), Business Development and was promoted to Chief Operating Officer in January 2022.
  • Pete Gelinas brings over 15 years of extensive experience in Manufacturing and CMC Product Development to AffyImmune.

Avenacy Announces New Product Launches and Participation in DCAT Week 2024

Retrieved on: 
Monday, March 18, 2024
Biotechnology, General Health, FDA, Health, Pharmaceutical, HER2, Combination therapy, Fulvestrant, Growth, AstraZeneca, Entrepreneurship, DCAT, Merck, Merck & Co., Woman, Syringe, Breast cancer, Safety, Multimedia, Food, Injection, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240318415023/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240318415023/en/
    “Avenacy has had a strong start to 2024, with two product launches already executed and two more newly announced additions to our rapidly expanding portfolio.
  • Avenacy will begin shipping Fosaprepitant for Injection and Fulvestrant Injection to wholesale partners this week.
  • To learn more about Avenacy’s products or the Company’s exciting growth plans for 2024, please see the Avenacy management team at DCAT Week 2024 taking place in New York City from March 18-21st.
  • To request a meeting with a member of the Avenacy team, please reach out to [email protected] .

US Digital Marketing Trends in Non-small Cell Lung Cancer: Merck's Keytruda.com Achieved the Highest Total Traffic Across NSCLC Patient Websites - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 14, 2024
Health, Oncology, AstraZeneca, Pfizer, Digital, Comparison, Patient, Roche, Social media, Merck, BMS, Lung cancer, DDA, HCP, Pharmaceutical industry

Merck's Keytruda.com achieved the highest total traffic across non-small cell lung cancer (NSCLC) patient sites in the US, with over 2.4 million visitors from October 2022 to September 2023.

Key Points: 
  • Merck's Keytruda.com achieved the highest total traffic across non-small cell lung cancer (NSCLC) patient sites in the US, with over 2.4 million visitors from October 2022 to September 2023.
  • Overall, the highest proportion of traffic to top branded patient NSCLC websites originated from direct and organic sources.
  • AstraZeneca's Imfinzihcp.com achieved the highest total traffic across NSCLC HCP sites in the US, with almost 300,000 visitors from October 2022 to September 2023.
  • Overall, the highest proportion of traffic to branded NSCLC websites for HCPs originated from direct sources, followed by paid and organic traffic.

BenevolentAI Unaudited Preliminary Results for the Year Ended 31 December 2023

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Pharmaceutical, Finance, Health, Artificial Intelligence, Health Technology, Professional Services, Technology, Knowledge, PDE10, Ulcerative colitis, Neurology, AstraZeneca, Atopic dermatitis, ALS, Glioblastoma, Drug discovery, Benevolence, Patient, GBM, Cash, UC, Chairperson, Research, Merck, IND, SBP, BAI, Retinoic acid receptor alpha, Safety, Euronext Amsterdam, Pharmaceutical industry

BenevolentAI (“BenevolentAI”, “the Company” or “the Group”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces its unaudited preliminary results for the twelve months ended 31 December 2023.

Key Points: 
  • BenevolentAI (“BenevolentAI”, “the Company” or “the Group”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces its unaudited preliminary results for the twelve months ended 31 December 2023.
  • Dr. Joerg Moeller, Chief Executive Officer (CEO) of BenevolentAI, said:
    "I am delighted to present my inaugural set of financial results as the CEO of BenevolentAI.
  • I look forward to working closely with them, and our partners, to make a lasting impact on the lives of patients worldwide."
  • Cash, cash equivalents and short-term deposits position of £72.9 million at 31 December 2023 (31 December 2022: £130.2 million), compared with £84.3 million at 30 June 2023.

Pearl Bio Inks Collaboration with Merck to Discover Novel Engineered Biologics

Retrieved on: 
Tuesday, March 12, 2024
Biotechnology, FDA, Diabetes, Health, Legal, Pharmaceutical, Professional Services, Oncology, Other Science, Research, Infectious Diseases, General Health, Genetics, Science, MSD, Entrepreneurship, Yale University, Partnership, Synthetic biology, Epitope, Khosla Ventures, Pearl, Merck & Co., Merck, GRO, Cancer, Stanford University, Scottish Register of Tartans, Pharmaceutical industry

Pearl Bio (a synthetic biology company backed by Khosla Ventures) today announced that it has entered a license, collaboration and option agreement with Merck, known as MSD outside of the United States and Canada, to discover biologic therapies comprising non-standard amino acids.

Key Points: 
  • Pearl Bio (a synthetic biology company backed by Khosla Ventures) today announced that it has entered a license, collaboration and option agreement with Merck, known as MSD outside of the United States and Canada, to discover biologic therapies comprising non-standard amino acids.
  • "Merck is excited to collaborate with Pearl, a pioneer in developing recoded organisms, to produce novel biologics enabled by synthetic chemistries,” shared Juan Alvarez, Vice President of Discovery Biologics at Merck Research Laboratories.
  • Backed by Khosla Ventures, Pearl Bio was launched by Scientific Co-Founders Drs.
  • (Pearl Bio) bringing together an exclusive platform technology to advance multi-functionalized biologics and biomaterials by encoding synthetic chemistries.

Caris Life Sciences Announces Partnership with Merck KGaA, Darmstadt, Germany to Discover Novel Cancer Targets and Accelerate First-In-Class Antibody Drug Conjugate Development

Retrieved on: 
Thursday, April 4, 2024
Merck Serono, Partnership, ADAPT, Patient, Neoplasm, Research, Health care, Merck, Cancer, Doctor of Philosophy, Spacecraft, Senior, Merck Group, Therapy, Machine learning, ADC, Pharmaceutical industry

Under the terms of the agreement, Merck KGaA, Darmstadt, Germany, will provide Caris with an upfront payment as well as research funding.

Key Points: 
  • Under the terms of the agreement, Merck KGaA, Darmstadt, Germany, will provide Caris with an upfront payment as well as research funding.
  • Merck KGaA, Darmstadt, Germany will receive an exclusive global license to develop, manufacture and commercialize ADC therapeutics for selected targets.
  • Caris Discovery leverages the scale of Caris' core molecular profiling business to discover novel, druggable targets that would be otherwise inaccessible through more traditional approaches.
  • "We are proud to be working closely with Merck KGaA, Darmstadt, Germany, to bring new therapeutic options to cancer patients together."